| 01/14 | Gilead withdraws use of Zydelig to treat two types of cancer | RE |
| 01/14 | Gilead withdraws use of Zydelig to treat two types of cancer | RE |
| 01/13 | WHO recommends Eli Lilly, GSK-Vir's drugs, widening COVID-19 treatment pool | RE |
| 01/13 | European ADRs Move Higher in Thursday Trading | MT |
| 01/13 | WHO, EMA Warn Against Repeated COVID-19 Booster Shots | MT |
| 01/13 | Countryside Slumps 17% as CEO Steps Down Amid Deal with Activist Investor | MT |
| 01/13 | Countryside Properties CEO Steps Down; Chair Named As Interim Successor | MT |
| 01/12 | Pfizer's Pneumonia Jab, COVID-19 Booster Shot Safe for Coadministration in Late-Stage S.. | MT |
| 01/12 | BIONTECH : Goldman Sachs reaffirms its Neutral rating | MD |
| 01/12 | Pfizer Says Pneumococcal Vaccine Combined with COVID-19 Shot Effective in Adults Above .. | MT |
| 01/12 | Pfizer Reports Positive Results From Study Co-Administering Vaccines for Covid-19, Pneu.. | DJ |
| 01/12 | South African Institute To Study Effects Of Pfizer, BioNTech, Johnson & Johnson Booster.. | MT |
| 01/11 | U.S. FDA amends J&J vaccine fact sheet to include rare bleeding risk | RE |
| 01/11 | BioNTech, InstaDeep Develop System to Predict High-Risk COVID-19 Variants | MT |
| 01/11 | European ADRs Nudge Lower in Tuesday Trading | MT |
| 01/11 | BioNTech Sees COVID-19 Vaccine Revenue of Up to 17 Billion Euros in 2021, 2022 | MT |
| 01/11 | BioNTech Says 2022 Vaccine Revenue Expected To Hit $19 Billion | MT |
| 01/11 | BioNTech, InstaDeep Develop Early Warning System To Flag High-Risk COVID-19 Variants | MT |
| 01/11 | BioNTech SE and InstaDeep Ltd Developed and Successfully Tested Early Warning System to.. | CI |
| 01/11 | Vertex's Cystic Fibrosis Combo Gets Extended EU Nod For Treating Children | MT |
| 01/11 | Vertex Secures European Commission's Approval for Kaftrio With Ivacaftor as Treatment f.. | MT |
| 01/11 | Vertex Pharmaceuticals Incorporated announces European Commission Approves KAFTRIO® (iv.. | CI |
| 01/10 | Gilead, Merck & Co. to Evaluate Lung Cancer Combo Therapy in Two Clinical Studies | MT |
| 01/10 | Pfizer CEO says Omicron-targeted vaccine is most likely outcome | RE |
| 01/10 | Gilead Sciences, Merck To Study Trodelvy, Keytruda Combination For Treatment of Lung Ca.. | MT |
| 01/10 | BioNTech Working With Crescendo Biologics on Immunotherapies for Cancers, Other Disease.. | MT |
| 01/10 | Gilead Announces Clinical Trial Collaborations With Merck to Evaluate Trodelvy® in Comb.. | CI |
| 01/10 | BioNTech Signs Collaboration Deal With Crescendo For Cancer And Other Treatments | MT |
| 01/10 | BioNTech SE and Crescendo Biologics Ltd Announce Global Collaboration to Develop Multi-.. | CI |
| 01/10 | Pfizer CEO says Omicron-targeted vaccine is most likely outcome | RE |
| 01/10 | Pfizer Signs Agreement to License Acuitas Therapeutics' Lipid Nanoparticle Technology | MT |
| 01/10 | Regeneron's Covid-19 Antibody Cocktail Had 2021 U.S. Sales Near $6 Billion | DJ |
| 01/09 | Pfizer, BioNTech Win Nod For COVID-19 Booster Shot In Qatar For Children Aged 12-15 Yea.. | MT |
| 01/07 | FDA Shortens Interval for Moderna's COVID-19 Booster Shot to Five Months | MT |
| 01/07 | US FDA Shortens Interval For Moderna's COVID-19 Vaccine Booster Shot to Five Months | MT |
| 01/07 | U.S. FDA cuts gap for Moderna COVID-19 booster dose as cases surge | RE |
| 01/07 | Regeneron Pharmaceuticals, Ultragenyx Pharmaceutical Strike Commercialization Deal for .. | MT |
| 01/07 | Regeneron, Ultragenyx Ink International Deal on Cholesterol Drug Evkeeza | DJ |
| 01/07 | Exclusive-Congressional watchdog warns U.S. health agency unprepared to take over COVID.. | RE |
| 01/07 | Regeneron Pharmaceuticals, Inc. and Ultragenyx Pharmaceutical Inc. Announce a License a.. | CI |
| 01/07 | South Africa Conducts Research Over Pfizer-BioNTech, Johnson & Johnson Vaccines' Booste.. | MT |
| 01/06 | Gilead Sciences, Inc. Announces Retirement of Brett A. Pletcher as Executive Vice Presi.. | CI |
| 01/06 | Morgan Stanley Downgrades Gilead Sciences to Equalweight From Overweight, Cuts Price Ta.. | MT |
| 01/06 | RBC Raises Price Target on Vertex Pharmaceuticals to $268 From $265, Maintains Outperfo.. | MT |
| 01/06 | RBC Lifts Price Target on Gilead Sciences to $87 From $86, Maintains Outperform Rating | MT |
| 01/06 | Pfizer-BioNTech COVID-19 Vaccine Approved For Children In Malaysia | MT |
| 01/06 | ANALYST RECOMMENDATIONS : Bank of America, Dollar General, Evercore, Reckitt Benckiser, Un.. | |
| 01/06 | Pfizer-BioNTech Booster Recommended by CDC For Children Above 12 | MT |
| 01/05 | Switzerland OKs Issue of COVID-19 Certificates For Novavax Vaccine | MT |
| 01/05 | CDC advisory panel in favor of Pfizer vaccine booster for ages 12 to 15 | RE |
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
